AUTONOMIX MEDICAL INC (AMIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$4.59-1.92%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AMIX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue managing capital allocation including warrant inducement agreements and modifications of security holder rights.
Stated as a priority in 2 recent disclosures in 2026. The company executed a warrant inducement agreement in August 2026 expected to raise approximately $4.9 million in gross proceeds and announced material modifications of security holder rights in June 2026. This shows active management of capital allocation and security holder rights with substantive recent transactions.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain compliance with Nasdaq listing requirements including corporate actions such as reverse stock split.
Newly stated in mid-2026 with the announcement of a 1-for-21 reverse stock split effective June 24, 2026, reducing shares outstanding from approximately 11.4 million to 543,000. This corporate action supports maintaining Nasdaq listing compliance as stated.
Continue efforts to control operating losses and reduce negative cash flow from operations.
Stated as a priority in 8 consecutive quarters through 2027-Q1. Operating income improved from negative $7.53 million in 2026-Q2 to negative $2.77 million in 2027-Q1, and net income improved from negative $11.41 million in 2025-Q4 to negative $2.73 million in 2027-Q1. Cash from operations remains negative at $3.54 million in 2027-Q1. The trajectory shows progress in reducing losses and cash burn but losses persist.
“Operating income was negative $2.77 million and net income negative $2.73 million.”
“Operating income negative $2.74 million and net income negative $2.67 million.”
“Operating income negative $3.34 million and net income negative $3.26 million.”
“Operating income negative $7.53 million and net income negative $7.45 million.”
“Operating income negative $3.42 million and net income negative $3.34 million.”
“Operating income negative $3.25 million and net income negative $11.41 million.”
“Operating income negative $2.75 million and net income negative $2.71 million.”
“Operating income negative $2.84 million and net income negative $2.81 million.”
Over the trailing year it converted 0.79x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, long-term interest rates, real (inflation-adjusted) rates, the US dollar, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.